*Note: For the investigational use of Adipose-Derived Stem Cells (ADSC’s) for clinical research and deployment.
Crohn’s disease is a type of inflammatory bowel disease that occurs in approximately half a million people in North America. It can affect any part of the gastrointestinal tract from the mouth to the anus, causing a wide variety of symptoms, including abdominal pain, bloating, diarrhea (which may be bloody if inflammation is at its worst), vomiting (can be continuous), or weight loss. Skin rashes and arthritis can also occur. Crohn’s disease has a genetic component, but it is an auto-immune disease in which the person’s own immune system attacks the gastrointestinal tract possibly directed at microbial antigens. The terminal ileum is the part of the bowel most often affected in this disease.
Treatment often includes immune-suppressant therapy with steroids. Antibiotics and anti-inflammatories are also used extensively. In Europe, stem cells are used commonly to treat Crohn’s. Research is ongoing to evaluate the effects of stem cells on auto-immune conditions.
Stem Cells and Crohn’s Disease
Dr. Todd Malan has remained in the forefront of developing stem cell therapies for use in treating autoimmune disease, including Crohn’s Disease. Stem cell therapy focuses on repairing tissue damage as a result of both chronic disease and the use of steroid-based medications for treatment. Successful treatment can provide symptom relief and remission for improved quality of life.
Regenerative Cell Medicine has developed a specific SVF deployment protocol that attempts to utilize the potential immune-modulatory, anti-inflammatory, and regenerative properties of SVF (rich in mesenchymal stem cells and growth factors). SVF is deployed systemically and may require repeat dosing. This is done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately three hours.